Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Mol Cell Biol ; 22(17): 6306-17, 2002 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-12167722

RESUMEN

DNA double-strand breaks (DSBs) arise spontaneously after the conversion of DNA adducts or single-strand breaks by DNA repair or replication and can be introduced experimentally by expression of specific endonucleases. Correct repair of DSBs is central to the maintenance of genomic integrity in mammalian cells, since errors give rise to translocations, deletions, duplications, and expansions, which accelerate the multistep process of tumor progression. For p53 direct regulatory roles in homologous recombination (HR) and in non-homologous end joining (NHEJ) were postulated. To systematically analyze the involvement of p53 in DSB repair, we generated a fluorescence-based assay system with a series of episomal and chromosomally integrated substrates for I-SceI meganuclease-triggered repair. Our data indicate that human wild-type p53, produced either stably or transiently in a p53-negative background, inhibits HR between substrates for conservative HR (cHR) and for gene deletions. NHEJ via microhomologies flanking the I-SceI cleavage site was also downregulated after p53 expression. Interestingly, the p53-dependent downregulation of homology-directed repair was maximal during cHR between sequences with short homologies. Inhibition was minimal during recombination between substrates that support reporter gene reconstitution by HR and NHEJ. p53 with a hotspot mutation at codon 281, 273, 248, 175, or 143 was severely defective in regulating DSB repair (frequencies elevated up to 26-fold). For the transcriptional transactivation-inactive variant p53(138V) a defect became apparent with short homologies only. These results suggest that p53 plays a role in restraining DNA exchange between imperfectly homologous sequences and thereby in suppressing tumorigenic genome rearrangements.


Asunto(s)
Daño del ADN , Reparación del ADN/fisiología , ADN/genética , Genes p53 , Proteína p53 Supresora de Tumor/fisiología , Linfocitos B , Línea Celular , Transformación Celular Neoplásica/genética , Codón/genética , ADN/metabolismo , Desoxirribonucleasas de Localización Especificada Tipo II/fisiología , Genes Reporteros , Proteínas Fluorescentes Verdes , Humanos , Células K562 , Proteínas Luminiscentes/genética , Modelos Genéticos , Plásmidos/genética , Proteínas Recombinantes de Fusión/fisiología , Recombinación Genética , Proteínas de Saccharomyces cerevisiae , Especificidad por Sustrato , Activación Transcripcional/genética , Proteína p53 Supresora de Tumor/genética
2.
Cell Cycle ; 5(1): 14-22, 2006 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-16357528

RESUMEN

Ectopic expression of the homeodomain transcription factor HOXB4 expands hematopoietic stem and progenitor cells in vivo and in vitro, making HOXB4 a highly interesting candidate for therapeutic stem cell expansion. However, when expressed at high levels, HOXB4 concomitantly perturbs differentiation and thus likely predisposes the manipulated cells for leukemogenesis. We therefore asked whether the expression level of HOXB4 may be a critical parameter that influences the growth and transformation properties of transduced cells. Using a set of retroviral vectors which covered a 40-fold range of expression levels, we studied the consequences of HOXB4 expression at different levels in the well established Rat-1 fibroblast cell system. HOXB4 transformed Rat-1 fibroblasts beyond a certain threshold level of expression. Further escalation of HOXB4 expression, however, did not enhance transformation. Instead, HOXB4 mediated a dose dependent anti-proliferative effect on Rat-1 and NIH3T3 fibroblasts. This effect was aggravated under reduced serum concentrations and was, at least partially, due to an enhanced sensitivity of HOXB4 overexpressing cells to induction of apoptosis. Based on these results we propose that HOXB4 affects cell growth in a dose-dependent manner by sensitizing cells towards extrinsic signals.


Asunto(s)
Proteínas de Homeodominio/metabolismo , Transducción de Señal/efectos de los fármacos , Factores de Transcripción/metabolismo , Animales , Línea Celular , Proliferación Celular , Relación Dosis-Respuesta a Droga , Regulación de la Expresión Génica , Vectores Genéticos/genética , Proteínas de Homeodominio/genética , Humanos , Ratones , Proteínas Proto-Oncogénicas c-myc/metabolismo , Ratas , Factores de Transcripción/genética
3.
Blood ; 101(5): 1759-68, 2003 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-12406897

RESUMEN

Ectopic retroviral expression of homeobox B4 (HOXB4) causes an accelerated and enhanced regeneration of murine hematopoietic stem cells (HSCs) and is not known to compromise any program of lineage differentiation. However, HOXB4 expression levels for expansion of human stem cells have still to be established. To test the proposed hypothesis that HOXB4 could become a prime tool for in vivo expansion of genetically modified human HSCs, we retrovirally overexpressed HOXB4 in purified cord blood (CB) CD34+ cells together with green fluorescent protein (GFP) as a reporter protein, and evaluated the impact of ectopic HOXB4 expression on proliferation and differentiation in vitro and in vivo. When injected separately into nonobese diabetic-severe combined immunodeficient (NOD/SCID) mice or in competition with control vector-transduced cells, HOXB4-overexpressing cord blood CD34+ cells had a selective growth advantage in vivo, which resulted in a marked enhancement of the primitive CD34+ subpopulation (P =.01). However, high HOXB4 expression substantially impaired the myeloerythroid differentiation program, and this was reflected in a severe reduction of erythroid and myeloid progenitors in vitro (P <.03) and in vivo (P =.01). Furthermore, HOXB4 overexpression also significantly reduced B-cell output (P <.01). These results show for the first time unwanted side effects of ectopic HOXB4 expression and therefore underscore the need to carefully determine the therapeutic window of HOXB4 expression levels before initializing clinical trials.


Asunto(s)
Hematopoyesis/fisiología , Proteínas de Homeodominio/fisiología , Linfocitos/citología , Células Mieloides/citología , Factores de Transcripción/fisiología , Animales , Retrovirus Endógenos/genética , Sangre Fetal/citología , Regulación de la Expresión Génica , Vectores Genéticos/genética , Proteínas de Homeodominio/genética , Proteínas de Homeodominio/toxicidad , Humanos , Interleucina-3/farmacología , Interleucina-6/farmacología , Células K562/citología , Virus de la Leucemia Murina/genética , Ratones , Ratones Endogámicos NOD , Ratones SCID , Proteínas Recombinantes de Fusión/fisiología , Proteínas Recombinantes de Fusión/toxicidad , Proteínas Recombinantes/farmacología , Factores de Transcripción/genética , Factores de Transcripción/toxicidad , Transducción Genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA